Showing results (91-100 of 164) with videos related to
Sort By:
Pageof 17
Translational Lung Cancer Research|August 12, 2022
Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with EGFR-mutated NSCLC: a case reportJavier Pozas, Víctor Albarrán-Fernández, Luis González-Campo, et al.International Journal of Molecular Sciences|April 13, 2023
GWAS-Identified Variants for Obesity Do Not Influence the Risk of Developing Multiple Myeloma: A Population-Based Study and Meta-AnalysisJosé Manuel Sánchez-Maldonado, Antonio José Cabrera-Serrano, Subhayan Chattopadhyay, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2016
Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi TechniqueCarlos Camps, Joan Albanell, Antonio Antón, et al.Cancers|November 25, 2023
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion MutationsPetros Christopoulos, Nicolas Girard, Claudia Proto, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2019
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLCTodd M Bauer, Benjamin Besse, Alex Martinez-Marti, et al.Clinical Lung Cancer|June 2, 2019
Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer PatientsLaura Mezquita, Amparo Benito, Alberto Ruano-Raviña, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 27, 2016
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish RegionsJavier Salvador, Jorge Aparicio, Francisco Javier Baron, et al.European Journal of Cancer (Oxford, England : 1990)|January 18, 2019
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancerBenjamin P Levy, Giuseppe Giaccone, Benjamin Besse, et al.Oncotarget|June 20, 2022
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access programReyes Bernabé-Caro, Pilar Garrido, Rosario García-Campelo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung CancerHelena A Yu, Luis G Paz-Ares, James Chih-Hsin Yang, et al.Pageof 17